Synaptamide modulates glial and neurotransmitter activity in the spinal cord during neuropathic pain

IF 2.7 4区医学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of chemical neuroanatomy Pub Date : 2023-11-05 DOI:10.1016/j.jchemneu.2023.102361

Anna Starinets, Arina Ponomarenko, Anna Tyrtyshnaia, Igor Manzhulo

{"title":"Synaptamide modulates glial and neurotransmitter activity in the spinal cord during neuropathic pain","authors":"Anna Starinets, Arina Ponomarenko, Anna Tyrtyshnaia, Igor Manzhulo","doi":"10.1016/j.jchemneu.2023.102361","DOIUrl":null,"url":null,"abstract":"<div><p>N-docosahexaenoylethanolamine, or synaptamide, is an endogenous metabolite of docosahexaenoic acid that is known for synaptogenic and neurogenic effects. In our previous studies we have shown that synaptamide attenuates neuropathic pain, facilitates remyelination, and reduces neuroinflammation after the chronic constriction injury (CCI) of the sciatic nerve in rats. In the current study, we show that daily synaptamide administration (4 mg/kg/day) within 14 days post-surgery: (1) decreases micro- and astroglia activity in the dorsal and ventral horns of the lumbar spinal cord; (2) modulates pro-inflammatory (IL1β, IL6) and anti-inflammatory (IL4, IL10) cytokine level in the serum and spinal cord; (3) leads to a rise in synaptamide and anandamide concentration in the spinal cord; (4) enhances IL10, CD206 and N-acylethanolamine-hydrolyzing acid amidase synthesis in macrophage cell culture following LPS-induced inflammation. Thus, the ability of synaptamide to modulate glial and cytokine activity indicates its potential for implementation in the treatment peripheral nerve injury.</p></div>","PeriodicalId":15324,"journal":{"name":"Journal of chemical neuroanatomy","volume":"134 ","pages":"Article 102361"},"PeriodicalIF":2.7000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of chemical neuroanatomy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S089106182300131X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

N-docosahexaenoylethanolamine, or synaptamide, is an endogenous metabolite of docosahexaenoic acid that is known for synaptogenic and neurogenic effects. In our previous studies we have shown that synaptamide attenuates neuropathic pain, facilitates remyelination, and reduces neuroinflammation after the chronic constriction injury (CCI) of the sciatic nerve in rats. In the current study, we show that daily synaptamide administration (4 mg/kg/day) within 14 days post-surgery: (1) decreases micro- and astroglia activity in the dorsal and ventral horns of the lumbar spinal cord; (2) modulates pro-inflammatory (IL1β, IL6) and anti-inflammatory (IL4, IL10) cytokine level in the serum and spinal cord; (3) leads to a rise in synaptamide and anandamide concentration in the spinal cord; (4) enhances IL10, CD206 and N-acylethanolamine-hydrolyzing acid amidase synthesis in macrophage cell culture following LPS-induced inflammation. Thus, the ability of synaptamide to modulate glial and cytokine activity indicates its potential for implementation in the treatment peripheral nerve injury.

查看原文本刊更多论文

突触酰胺在神经性疼痛过程中调节脊髓中的神经胶质和神经递质活性。

N-二十二碳六烯酸乙醇胺，或称突触酰胺，是二十二碳六油酸的内源性代谢产物，具有突触发生和神经发生作用。在我们之前的研究中，我们已经表明，突触酰胺可以减轻大鼠坐骨神经慢性收缩损伤（CCI）后的神经性疼痛，促进髓鞘再生，并减少神经炎症。在目前的研究中，我们发现在手术后14天内每天给予突触酰胺（4mg/kg/天）：（1）降低腰椎背角和腹角的微胶质细胞和星形胶质细胞活性；（2）调节血清和脊髓中的促炎（IL1β，IL6）和抗炎（IL4，IL10）细胞因子水平；（3）导致脊髓中突触酰胺和阿那达明浓度升高；（4）增强LPS诱导的炎症后巨噬细胞培养中IL10、CD206和N-酰基乙酰胺水解酸酰胺酶的合成。因此，突触酰胺调节神经胶质和细胞因子活性的能力表明其在治疗周围神经损伤中的应用潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of chemical neuroanatomy 医学-神经科学

CiteScore

4.50

自引率

3.60%

发文量

审稿时长

62 days

期刊介绍： The Journal of Chemical Neuroanatomy publishes scientific reports relating the functional and biochemical aspects of the nervous system with its microanatomical organization. The scope of the journal concentrates on reports which combine microanatomical, biochemical, pharmacological and behavioural approaches. Papers should offer original data correlating the morphology of the nervous system (the brain and spinal cord in particular) with its biochemistry. The Journal of Chemical Neuroanatomy is particularly interested in publishing important studies performed with up-to-date methodology utilizing sensitive chemical microassays, hybridoma technology, immunocytochemistry, in situ hybridization and receptor radioautography, to name a few examples. The Journal of Chemical Neuroanatomy is the natural vehicle for integrated studies utilizing these approaches. The articles will be selected by the editorial board and invited reviewers on the basis of their excellence and potential contribution to this field of neurosciences. Both in vivo and in vitro integrated studies in chemical neuroanatomy are appropriate subjects of interest to the journal. These studies should relate only to vertebrate species with particular emphasis on the mammalian and primate nervous systems.